Question

In: Economics

Describe some ways that the SARS-CoV-2 (Covid-19) pandemic will affect the following aspects of trade between...

Describe some ways that the SARS-CoV-2 (Covid-19) pandemic will affect the following aspects of trade between the US and China over the next 5 years.

(a) The volume of trade?

(b) The pattern of trade, i.e., what each country exports to the other?

(c) The US trade deficit with China?

Solutions

Expert Solution

We have previously reported on the Economic and Trade Agreement between the United States and China ("Phase One Trade Deal"), which entered into force on February 14, 2020.1 This Legal Update reports on implementation of the Phase One Trade Deal and the impact, if any, of the COVID-19 outbreak on the US-China trade relationship.

The View from the United States

The response to COVID-19 in the United States has been on a different cycle and scale than the response to the outbreak in China. Whereas China is already beginning to relax widespread and dramatic restrictions on the movement of people within its borders, the United States is just beginning to close schools, cancel sporting events and in some cases (e.g., New York City) declare states of emergency. For now, though, the federal government's approach to trade with China has been, for the most part, "business as usual."

As it has been for many months, the Office of the United States Trade Representative (USTR) continues to grant limited, product-specific exclusions to the tariffs previously imposed by the United States on a majority of goods imported from China. The most recent set of exclusions, announced March 10, 2020,2 exempts certain products from an additional 7.5 percent duty imposed by the United States on September 1, 2019. The tariff exclusions granted this week will be effective from September 1, 2019, until September 1, 2020. US Customs and Border Protection will issue instructions on entry guidance and implementation.

Some of these exclusions cover medical devices and products, including sanitary wipes, medical gloves, face masks, surgical gowns and other items that are needed in the fight against COVID-19. However, these exclusions do not appear to signal a new or dramatically different approach to trade with China as a result of the COVID-19 outbreak in the United States. Numerous tariff exclusion requests covering medical devices have been denied, and presumably this trend will continue for those devices not directly related to COVID-19 prevention and treatment. Indeed, when asked recently whether the United States might relax tariffs on China in order to stimulate the economy and address the COVID-19 outbreak, White House trade adviser Peter Navarro flatly said "no" and characterized any suggestions to the contrary as "absurd."3

The tariffs imposed by the Trump administration on China have forced many businesses to rethink their supply chains based in China. The COVID-19 outbreak and the national security concerns focused on Huawei and ZTE have only served to accelerate those recalculations and efforts. In short, the exigencies of the COVID-19 outbreak may force the United States to relax certain tariffs on certain products with an "eye" to fighting the virus, but we do not expect the White House to "chart a new course" with respect to China, especially in the long term.

The View from China

Since the beginning of 2020, China has adopted numerous measures to confront the outbreak of COVID-19 within its borders. As noted above, China has begun to relax some of these measures in recent weeks.

As part of its response to COVID-19, China, like the US, has relaxed tariffs and other restrictions on certain products needed to fight the outbreak. Specifically, on February 1, 2020, China announced that for certain US goods (e.g., reagents, fire trucks, and disinfectants) imported pursuant to China’s new temporary “Tax Exemption Policy”4 (which was issued on the same day) and for purposes of preventing and controlling the COVID-19 outbreak, tariffs imposed by China in response to US trade actions would not apply during the period of January 1 to March 31, 2020.5

At the same time that it has been fighting the COVID-19 outbreak, China’s efforts to implement the Phase One Trade Deal have continued. For example, in February 2020, China lowered the ad valorem rates for additional tariffs imposed on US goods under its latest round of countermeasures to US tariffs pursuant to Section 301,6 and granted new product exclusions for US products captured by a previous round, which are effective from February 28, 2020, to February 27, 2021.7

Furthermore, on March 2, 2020, China implemented a new tariff exclusion process for "market-based purchases."8 Under this new tariff exclusion process, a China-based importer may file an exclusion request for any products included on the eligible product list published together with the official announcement of the new process. Eligible products span across all previous rounds of China’s Section 301 countermeasures. The term “market-based purchases” indicates that this new process bears a relationship to China’s purchase obligations under the Phase One Trade Deal.

In sum, China has not let the COVID-19 outbreak stop it from implementing the Phase One Trade Deal with the United States. If anything, China's efforts to control the virus have caused it to further relax countermeasures previously adopted in order to respond to US tariffs and other trade measures, at least in the short term. However, the significant economic loss caused by the COVID-19 outbreak and its aftermath might create some difficulties for China to keep pace with its purchase obligations under the Phase One Trade Deal. The exact impact, if any, on China’s “market-based purchases” of US products under the agreement remains to be seen.

Where Things Go from Here

US tariffs and other restrictions on Chinese goods and services during 2018 and 2019 shook the markets. China's countermeasures did the same. Businesses large and small in both countries had to adapt. COVID-19 is placing new pressures on business and the markets. No one, including the White House, saw this coming. Moreover, it comes less than nine months before the next presidential election in the United States. Regardless of who is ahead in the polls or who wins the election, trade officials in Beijing and Washington will presumably try to minimize any disruptions or shocks during the remainder of 2020. As part of this effort, trade officials will likely signal progress in the effort to conclude a Phase Two Trade Deal. However, once we get past the November election, hopefully COVID-19 will be in our rearview mirror and reality will set in. That reality should include a healthy scepticism that China and the United States can move past their differences and conclude a Phase Two Trade Deal anytime soon.  


Related Solutions

With all that you know about SARS-CoV-2 and Covid-19, discuss a possible evolutionary scenario for SARS-CoV-2...
With all that you know about SARS-CoV-2 and Covid-19, discuss a possible evolutionary scenario for SARS-CoV-2 , over the next 6 months, 1 year and 5 years. How, if at all, will the virulence/trasmissability of SARS-CoV-2 change and why? A vaccine was developed for Polio, but, so far, not for HIV. Will science develop an effective vaccine against SARS-CoV-2? Why or why not?
Consider the epidemiological approach and the questions related to health events and health concerns. Answer these questions in relation to the SARS-CoV-2 (COVID-19) pandemic.
Critical Thinking.Consider the epidemiological approach and the questions related to health events and health concerns. Answer these questions in relation to the SARS-CoV-2 (COVID-19) pandemic.
COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and is closely related...
COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and is closely related to SARS-CoV-1 (Severe Acute Respiratory Syndrome Coronavirus 1) and MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus). Imaging studies have shown that COVID-19 results in pneumonia with “ground-glass opacification, consolidation, bilateral involvement, and peripheral and diffuse distribution.” (Lee et al (2020); The Lancet, 20(4), 384). Ground-glass opacification: Consolidation: Bilateral involvement: Peripheral and diffuse distribution:
COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and is closely related...
COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and is closely related to SARS-CoV-1 (Severe Acute Respiratory Syndrome Coronavirus 1) and MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus). Imaging studies have shown that COVID-19 results in pneumonia with “ground-glass opacification, consolidation, bilateral involvement, and peripheral and diffuse distribution.” (Lee et al (2020); The Lancet, 20(4), 384). Ground-glass opacification: Consolidation: Bilateral involvement: Peripheral and diffuse distribution:
People infected with SARS- CoV-2 (the coronavirus that causes COVID-19) can show an array of different...
People infected with SARS- CoV-2 (the coronavirus that causes COVID-19) can show an array of different symptoms and complications, ranging from mild to severe. Researchers are working to develop both prevention and treatment, including vaccines and antibody injections. Vaccines introduce antigens from viruses, without introducing the infectious virus itself. How/why do vaccines act as prevention rather than treatment? Be sure to talk about the types of cells and immune responses that vaccines are targeting, and why targeting these cells and...
COVID-19 is a disease caused by SARS-CoV-2. This coronavirus infection results in an acute respiratory infection...
COVID-19 is a disease caused by SARS-CoV-2. This coronavirus infection results in an acute respiratory infection that can lead to viral pneumonia and end-organ failure. CoV-2 is a RNA virus (single stranded RNA genome) that specifically targets cells in the lungs that express the ACE2 receptor. Answer the three related questions regarding a mucosal immune response to SARS-CoV-2: 1. Which antibody class would you expect to encounter CoV-2 and which T effector T cell would activate B cells? As the...
1. Explain how an ELISA can be used to detect SARS-CoV-2 (the virus that causes COVID-19)...
1. Explain how an ELISA can be used to detect SARS-CoV-2 (the virus that causes COVID-19) and the steps involved. 2. An ELISA would be ineffective for detecting SARS-CoV-2 during early symptomatic infection because the antibodies take a long time to form. True False
1. Explain how an ELISA can be used to detect SARS-CoV-2 (the virus that causes COVID-19)...
1. Explain how an ELISA can be used to detect SARS-CoV-2 (the virus that causes COVID-19) and the steps involved. 2. An ELISA would be ineffective for detecting SARS-CoV-2 during early symptomatic infection because the antibodies take a long time to form. True False
SARS-CoV-2, the virus that causes CoVid-19, belongs to the Coronaviridae family. Viruses under this family have...
SARS-CoV-2, the virus that causes CoVid-19, belongs to the Coronaviridae family. Viruses under this family have a genome made of single-stranded positive-sense RNA. Is this similar to the viral genome of HIV? If so, do you think that – in theory – they would have similar replication cycles?
Describe the basic structure of the coronavirus, SARS-CoV2. What is the difference between SARS-CoV2 and COVID-19?...
Describe the basic structure of the coronavirus, SARS-CoV2. What is the difference between SARS-CoV2 and COVID-19? How does the virus infect our body cells? How does the structure of the viral coat interact with the structure of the plasma membrane of human cells to facilitate entry of the virus? Once the virus has entered the cells, how does it "hijack"organelles in the human cell to do its own work of protein synthesis and replication? Which organs does the virus infect?...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT